Verapamil Articles
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
IMPACT OF SWEDISH REFERENCE PRICING
10 January 1994
KNOLL SIGNS DEAL WITH SIBERIAN COs
10 January 1994
IVAX AND KNOLL REACH AGREEMENT
10 January 1994
IVAX SEES NICHEPRODUCTS AS ITS FUTURE
20 December 1993
BASF TO PRODUCE IN SIBERIA
20 December 1993
US 3rd QUARTER RESULTS - SOME IMPROVEMENT
6 December 1993
NEW CANCER THERAPIES MOVE INTO THE CLINIC
4 October 1993
BULGARIA - SUCCESS FOR NIHFI LTD
13 September 1993
KNOLL AHEAD IN 1992 BUT 1st QTR FALLS
3 May 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
PFIZER DISREGARDS WSJ "SCARE STORY"
15 February 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
IVAX ALMOST "FULLY FLEDGED DRUG CO"
21 December 1992
ASTRA IS CHEM INSIGHT'S STAR PERFORMER
14 December 1992
US CHEMICAL/PHARMA COS' POOR PERFORMANCE
9 November 1992
GERMAN HEALTH REFORMS DEPRESS BASF
9 November 1992
IVAX NOTIFICATION
2 November 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
IVAX MARKETING
7 September 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
HYPERTENSION OPTIMAL TREATMENT STUDY
22 June 1992
STRONG EXPANSION AT KNOLL IN 1991
13 April 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
